


Attorney Docket No.: 2605-1-004N

AMENDMENT TO THE CLAIMS

1. (previously presented) A compound of formula 1

**I**

wherein:

- (i) n is an integer with a value ranging from ~~one~~ two to six;
- (ii) each R₁ is independently selected from:
 - hydrogen,
 - alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, aralkyl, aralkenyl, aralkynyl,
 - halo, haloalkyl,
 - hydroxyl, alkoxyl, hydroxyalkyl, alkoxyalkoxyl, acyl, carboxylate, carboxyl, alkanoyloxy,
 - nitrate, nitrite, nitrile, cyanate, isocyanate, primary amino, secondary amino, tertiary amino, azido, carboxamido, acylamino,
 - thiol, sulfonyl, alkyl sulfonate, aryl sulfonate, sulfonamide, thioaryloxy, thioalkoxy,
 - oxygen heterocycles, nitrogen heterocycles and sulfur heterocycles;
- (iii) R₂, R₃ and R₅ are each independently selected from hydrogen, alkyl and cycloalkyl; and

Attorney Docket No.: 2605-1-004N

(iv) R_4 is selected from alkyl, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl and aralkyl, provided that:

- a) when n is ~~1 or~~ 2 and R_4 is tert-butyl, benzyl or methyl, the R_1 s, R_2 , R_3 and R_5 are not all hydrogens; and
 - b) when n is 4 and R_4 is cyclohexyl the R_1 s, R_2 s, R_3 s and R_5 are not all hydrogen.
2. (previously presented) The compound of claim 1 wherein the R_1 groups include hydrogens and from zero up to three nonhydrogens selected from alkyl, alkoxy, alkoxyalkoxyl, hydroxy, amino, dialkylamino, acylamino, sulfonyl, sulfonate, sulfonamide, acyl, and aryl.
 3. (previously presented) The compound of claim 1 wherein R_1 includes 1-5 halogens.
 4. (previously presented) The compound of claim 1 wherein n is an integer having a value of from 2 through 4.
 5. (previously presented) The compound of claim 1 wherein $n=2$ or 3 and R_2 , R_3 and R_5 are all hydrogens and up to two lower alkyls.
 6. (previously presented) The compound of claim 2 wherein $n=2$ or 3 and R_2 , R_3 and R_5 are all hydrogens and up to two lower alkyls.

Attorney Docket No.: 2605-1-004N

7. (previously presented) The compound of claim 5 wherein R₁ and R₄ are selected from the group consisting of:

R ₁	R ₄
H	C(CH ₃) ₃
4-Me	C(CH ₃) ₃
4-iso-Pr	C(CH ₃) ₃
4-OH	C(CH ₃) ₃
4-OMe	C(CH ₃) ₃
4-OCH ₂ OMe	C(CH ₃) ₃
4-OEt	C(CH ₃) ₃
4-NMe ₂	C(CH ₃) ₃
4-NHAc	C(CH ₃) ₃
4-F	C(CH ₃) ₃
4-Cl	C(CH ₃) ₃
2-SO ₃ Na	C(CH ₃) ₃
2,4-di-SO ₃ Na	C(CH ₃) ₃
3,5-di-t-Bu-4-OH	C(CH ₃) ₃
3,5-di-t-Bu-4-OCH ₂ OMe	C(CH ₃) ₃
2-OH	C(CH ₃) ₃
2-OEt	C(CH ₃) ₃

8. (previously presented) The compound of claim 1 selected from the group consisting of:

Compound 2 *N-tert*-butyl-C-{2-[4-(methoxymethoxy)phenyl]ethyl} nitrone

Compound 3 *N-tert*-butyl-C-[2-(4-hydroxyphenyl)ethyl] nitrone

Compound 4 *N-tert*-butyl-C-[2-(4-methoxyphenyl)ethyl] nitrone

Compound 5 *N-tert*-butyl-C-[4-(tetrahydropyran-2-yloxy) phenyl] nitrone

Attorney Docket No.: 2605-1-004N

- Compound 6 *N*-tert-butyl-C-[2-(4-isopropoxyphenyl)ethyl] nitrone
Compound 7 *N*-tert-butyl-C-[2-(4-ethoxyphenyl)ethyl] nitrone
Compound 8 *N*-tert-butyl-C-[2-(4-benzenesulfonyloxy)phenyl]ethyl] nitrone
Compound 9 *N*-tert-butyl-C-[2-(4-acetamidophenyl)ethyl] nitrone
Compound 10 *N*-tert-butyl-C-[2-(4-benzenesulfonamidophenyl)ethyl] nitrone
Compound 11 *N*-tert-butyl-C-[2-(4-N,N-dibenzenesulfimidophenyl)ethyl] nitrone
Compound 12 *N*-tert-butyl-C-(5-phenylpentyl) nitrone
Compound 13 *N*-tert-butyl-C-[2-(4-isopropylphenyl)-1-methylethyl] nitrone
Compound 14 *N*-tert-butyl-C-(4-phenylpropyl) nitrone
Compound 15 *N*-tert-butyl-C-[1-(4-tert-butyl benzyl)-ethyl] nitrone
Compound 16 *N*-tert-butyl-C-[1-methyl-2-(4-methoxyphenyl)ethyl] nitrone
Compound 18 *N*-cyclohexyl-C-(2-phenylethyl) nitrone
Compound 19 *N*-tert-butyl-C-[4-phenylbutyl] nitrone
Compound 21 *N*-tert-butyl-C-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl] nitrone
Compound 22 *N*-tert-butyl-C-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)methyl] nitrone
Compound 23 *N*-tert-butyl-C-[4-methoxy-phenyl)propyl] nitrone,

and pharmaceutically acceptable salts thereof.

9. (previously presented) A nitrone compound having at least a Ph-Z-C(R)=N(=O)- where Ph represents a substituted or unsubstituted aryl moiety, and Z is a saturated aliphatic carbon chain of ~~one~~ two to six carbon atoms in length covalently bonded intermediate the aryl moiety and the nitrone carbon provided that:

when Z is $-\text{CH}_2-\text{CH}_2-$, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to either t-butyl or methyl; and

when Z is $-\text{CH}_2-(\text{CH}_2)_3-$, R is H, and Ph is unsubstituted aryl, the N atom of the nitrone is not coupled to cyclohexyl.

10. (previously presented) The nitrone compound of claim 9 wherein Z is a straight chain alkylene.

Attorney Docket No.: 2605-1-004N


11. (previously presented) The nitron compound of claim 9 wherein Z is a branched chain alkylene.
12. (cancelled)
13. (previously presented) The nitron compound of claim 10 wherein Z is ethylene.
14. (previously presented) The nitron compound of claim 10 wherein Z is n-propylene.
15. (previously presented) The nitron compound of claim 10 wherein Z is n-butylene.
16. (previously presented) The nitron compound of claim 11 wherein Z is isopropylene.
17. (previously presented) The nitron compound of claim 9 wherein the nitron nitrogen is coupled to a lower alkyl.
18. (previously presented) The nitron compound of claim 17 wherein the lower alkyl is methyl.
19. (previously presented) The nitron compound of claim 17 wherein the lower alkyl is tert-butyl.
20. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is substituted phenyl.
21. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two sulfonyls.

Attorney Docket No.: 2605-1-004N

22. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two lower alkyls and one hydroxyl.

23. (previously presented) The nitron compound of claim 10 wherein the aryl moiety is phenyl substituted with one or two alkoxyis.

24. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of formula I as active ingredients.



I

wherein:

- (i) n is an integer with a value ranging from ~~one~~ two to six;
- (ii) each R₁ is independently selected from:
 hydrogen,
 alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, aralkyl, aralkenyl,
 aralkynyl,
 halo, haloalkyl,
 hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkoxy, acyl, carboxylate, carboxyl,
 alkanoyloxy,
 nitrate, nitrite, nitrile, cyanate, isocyanate, primary amino, secondary amino,
 tertiary amino, azido, carboxamido, acylamino,
 thiol, sulfonyl, alkyl sulfonate, aryl sulfonate, sulfonamide, thioaryloxy,
 thioalkoxy,
 oxygen heterocycles, nitrogen heterocycles and sulfur heterocycles;
- (iii) R₂, R₃ and R₅ are each independently selected from hydrogen, alkyl and cycloalkyl; and

Attorney Docket No.: 2605-1-004N

(iv) R_4 is selected from alkyl, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl and aralkyl.

25. (previously presented) The composition of claim 24 wherein the R_1 groups include hydrogens and from zero up to three nonhydrogens selected from alkyl, alkoxy, alkoxyalkoxyl, halo, hydroxy, amino, dialkylamino, acylamino, sulfonyl, sulfonate, sulfonamide, acyl, and aryl.

26. (currently amended) The composition of claim 24 wherein n is an integer having a value of from ± 2 through 4.

27. (currently amended) The composition of claim 24 wherein ~~$n = 1$ and R_2, R_3 and R_4 are together all hydrogen or two hydrogens and one lower alkyl; and materials in which $n = 2$ or 3 and R_2, R_3 and R_4 are all hydrogens and up to two lower alkyls.~~

28. (currently amended) The composition of claim 24 wherein ~~$n = 1$ and R_2, R_3 and R_4 are together all hydrogen or two hydrogens and one lower alkyl; and materials in which $n = 2$ or 3 and R_2, R_3 and R_4 are all hydrogens and up to two lower alkyls.~~

29. (previously presented) The composition of claim 27 wherein R_1 and R_4 are selected from the group consisting of:

R_1	R_4
H	$C(CH_3)_3$
4-Me	$C(CH_3)_3$
4-iso-Pr	$C(CH_3)_3$
4-OH	$C(CH_3)_3$
4-OMe	$C(CH_3)_3$
4-OCH ₂ OMe	$C(CH_3)_3$
4-OEt	$C(CH_3)_3$
4-NMe ₂	$C(CH_3)_3$

Attorney Docket No.: 2605-1-004N

R ₁	R ₄
4-NHAc	C(CH ₃) ₃
4-F	C(CH ₃) ₃
4-Cl	C(CH ₃) ₃
2-SO ₃ Na	C(CH ₃) ₃
2,4-di-SO ₃ Na	C(CH ₃) ₃
3,5-di-t-Bu-4-OH	C(CH ₃) ₃
3,5-di-t-Bu-4-OCH ₂ OMe	C(CH ₃) ₃
2-OH	C(CH ₃) ₃
2-OEt	C(CH ₃) ₃

30. (previously presented) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and as active ingredients one or more compounds selected from the group consisting of:

- Compound 1 *N*-tert-butyl-C-(2-phenylethyl) nitrone
- Compound 2 *N*-tert-butyl-C-{2-[4-(methoxymethoxy)phenyl]ethyl} nitrone
- Compound 3 *N*-tert-butyl-C-[2-(4-hydroxyphenyl)ethyl] nitrone
- Compound 4 *N*-tert-butyl-C-[2-(4-methoxyphenyl)ethyl] nitrone
- Compound 5 *N*-tert-butyl-C-[4-(tetrahydropyran-2-yloxy) phenyl] nitrone
- Compound 6 *N*-tert-butyl-C-[2-(4-isopropoxyphenyl)ethyl] nitrone
- Compound 7 *N*-tert-butyl-C-[2-(4-ethoxyphenyl)ethyl] nitrone
- Compound 8 *N*-tert-butyl-C-[2-(4-benzenesulfonyloxy)phenyl]ethyl] nitrone
- Compound 9 *N*-tert-butyl-C-[2-(4-acetamidophenyl)ethyl] nitrone
- Compound 10 *N*-tert-butyl-C-[2-(4-benzenesulfonamidophenyl)ethyl] nitrone
- Compound 11 *N*-tert-butyl-C-[2-(4-N,N Dibenzenesulfimidophenyl)ethyl] nitrone
- Compound 12 *N*-tert-butyl-C-(5-phenylpentyl) nitrone
- Compound 13 *N*-tert-butyl-C-[2-(4-isopropylphenyl)-1-methylethyl] nitrone
- Compound 14 *N*-tert-butyl-C-(4-phenylpropyl) nitrone
- Compound 15 *N*-tert-butyl-C-[1-(4-tert-butyl benzyl)-ethyl] nitrone
- Compound 16 *N*-tert-butyl-C-[1-methyl-2-(4-methoxyphenyl)ethyl] nitrone

Attorney Docket No.: 2605-1-004N

~~Compound 17~~ ~~*N-tert-butyl-C-phenylmethyl*~~ ~~nitrone~~Compound 18 *N-cyclohexyl-C-(2-phenylethyl)* nitroneCompound 19 *N-tert-butyl-C-[4-phenylbutyl]* nitroneCompound 20 *N-tert-butyl-C-[1-(phenyl)ethyl]* nitroneCompound 21 *N-tert-butyl-C-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl]* nitroneCompound 22 *N-tert-butyl-C-[2-(3,5-di-tert-butyl-4-ydroxyphenyl)methyl]* nitroneCompound 23 *N-tert-butyl-C-[4-methoxy-phenyl)propyl]* nitrone,

and pharmaceutically acceptable salts thereof.

31. (previously presented) A pharmaceutical composition comprising a pharmaceutical carrier and, as an active ingredient at least one nitrone compound, the nitrone compound comprising at least a Ph-Z-C=N(=O) - where Ph represents a substituted or unsubstituted aryl moiety, and Z is a saturated aliphatic carbon chain of one to six carbon atoms in length covalently bonded intermediate the aryl moiety and the nitrone carbon.

32. (previously presented) The pharmaceutical composition of claim 31 wherein Z is a straight chain alkylene.

33. (previously presented) The pharmaceutical composition of claim 31 wherein Z is a branched chain alkylene.

34. (previously presented) The pharmaceutical composition of claim 32 wherein Z is methylene.

35. (previously presented) The pharmaceutical composition of claim 32 wherein Z is ethylene.

36. (previously presented) The pharmaceutical composition of claim 32 wherein Z is n-propylene.

Attorney Docket No.: 2605-1-004N

37. (previously presented) The pharmaceutical composition of claim 32 wherein Z is n-butylene.
38. (previously presented) The pharmaceutical composition of claim 32 wherein Z is isopropylene.
39. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the carrier is an injectable carrier.
40. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the composition is a solid carrier.
41. (previously presented) The pharmaceutical composition of any of claims 24-38 wherein the composition is a unit dose form.
42. (withdrawn) A method for treating or preventing inflammation in a mammal comprising administering said mammal an effective inflammation treating or preventing dose of a pharmaceutical composition according to any of claims 24-41.
43. (withdrawn) A method for treating or preventing neuropathic pain in a mammal comprising administering said mammal an effective neuropathic pain treating or preventing dose of a pharmaceutical composition according to any of claims 24-41.
44. (withdrawn) A method for the treatment of traumatic injury to the brain or spinal cord of a mammal comprising administering said mammal an effective brain or spinal cord injury treating dose of a pharmaceutical composition according to any of claims 24-41.
45. (withdrawn) The method of any of claims 42-44 wherein the mammal is a human.